Athira Pharma wins $15M grant from National Institute on Aging for trial of Alzheimer’s drug
Seattle-based Athira Pharma announced that it received a three-year grant totaling $15 million from the National Institute on Aging. The funding will support an upcoming clinical trial of a treatment that seeks to stop the deterioration of neurons and restore healthy brain activity in people with mild to moderate cases of Alzheimer’s disease. This follows the company’s initial public offering in September that raised $186 million.